---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-007388"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:06:44.869727+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed Pharmaceuticals raises $5.2M through private placement and option exercise

## Summary
- Gross proceeds ~$5.2M from sale of 3,012,049 pre-funded warrants and options; existing holders exercised 3,272,733 options at $0.83.
- Issued new preferred investment options to purchase up to 6,545,466 shares at $0.83, exercisable immediately, expire in 5.5 years.
- H.C. Wainwright acted as exclusive placement agent; received 7.5% cash fee and warrants for 408,511 shares at $1.0375.
- Proceeds to fund pipeline development, BayMedica commercial sales, and general working capital.
- Securities unregistered; company to file resale registration statement within 50-80 days of closing.

## SEC filing metadata
- accession: 0001013762-23-007388
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/0001013762-23-007388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/ea187408-8k_inmedpharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-007388
- JSON: https://secwatch.observer/filing/0001013762-23-007388.json
- Plain text: https://secwatch.observer/filing/0001013762-23-007388.txt

## Key facts
- Material Agreements
  InMed Pharmaceuticals Inc. entered into Purchase Agreement with two institutional accredited investors.
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: two institutional accredited investors
  source text: On October 24, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with two institutional accredited investors (the “Purchasers”), for the sale and issuance of an aggregate of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.83 per share (or pre-funded warrant in lieu thereof).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000101376223007388/0001013762-23-007388-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.